Biosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...

Biocon and Mylan are engaged in a court battle in India against Swiss biotech firm Roche over marketing restrictions imposed on their trast...

Biosimilar drugs are follow-on biologics that have nearly the same efficacy as the original drug and used to treat cancer or autoimmune dis...

The counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche’...

On May 9, the NPPA issued a notification capping the price of trastuzumab 440mg/50ml injections at Rs 55,812.29 per pack.

The judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.

The order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...

Zydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...

"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...

Bangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...

Canmab is considered a breakthrough in biosimilar drugs and is expected to treat about 35,000 breast cancer patients in the country.

Biocon plunged nearly 6% on Thursday, after its net profit rose 14% to Rs 105 crore for the quarter ended December 31 which was largely in ...

Indian markets are likely to trade in a range. Here is a list of ten stocks which are likely to be in focus in trade today.

Priced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.

Biotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next ...

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.